A bill to require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.

Accountability in Opioid Advertising Act This bill requires the Food and Drug Administration to prioritize the review of advertising and other promotional materials for drug for serious, life-threatening diseases or conditions or substance use disorders, especially opioids (drugs with effects similar to opium, such as certain pain medications) and drugs used in the treatment of opioid use disorders.